{"id":6991,"date":"2025-05-28T11:05:17","date_gmt":"2025-05-28T09:05:17","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=pipelines&p=6991"},"modified":"2025-07-10T11:04:06","modified_gmt":"2025-07-10T09:04:06","slug":"tislelizumab-pd-1-mab","status":"publish","type":"pipelines","link":"https:\/\/beonemedaffairs.com\/us\/pipelines\/6991\/tislelizumab-pd-1-mab\/","title":{"rendered":"Tislelizumab (PD-1 mAb)"},"content":{"rendered":"","protected":false},"template":"","meta":{"_acf_changed":false,"editor_notices":[]},"class_list":["post-6991","pipelines","type-pipelines","status-publish","hentry","molecule-tislelizumab","compound_type-mab"],"acf":{"indications_repeater":[{"indication":"1L NonSq NSCLC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"1L Sq NSCLC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"2\/3L NSCLC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"Neo\/adj NSCLC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"1L ES-SCLC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"1L ESCC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"2L ESCC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"LA ESCC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"1L GC\/GEJC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"1L NPC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"1L HCC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"1L UBC","disease_state":null,"phase":3,"countries":[],"status":"ongoing"},{"indication":"2\/3L HCC","disease_state":null,"phase":2,"countries":[],"status":"ongoing"},{"indication":"1L NSCLC (subcutaneous formulation)","disease_state":null,"phase":1,"countries":[],"status":"ongoing"}],"cancer_type":["46"],"compound_type":420,"custom_link":{"title":"Mode of Action video","url":"https:\/\/beonemedaffairs.com\/us\/936\/tislelizumab-moa-video\/","target":""}},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/pipelines\/6991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/pipelines"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/pipelines"}],"acf:term":[{"embeddable":true,"taxonomy":"compound_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/compound_type\/420"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}